^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SNHG10 (Small Nucleolar RNA Host Gene 10)

    i
    Other names: SNHG10, Small Nucleolar RNA Host Gene 10, NCRNA00063, LINC00063, TP53LC16, Small Nucleolar RNA Host Gene 10, Long Intergenic Non-Protein Coding RNA 63, FLJ40557, C14orf62, Chromosome 14 Open Reading Frame 62, Non-Protein Coding RNA 63, NONHSAG015797.2, NONHSAG015798.2, HSALNG0103440, Lnc-SYNE3-3, SNHG10
    Associations

    News

    Trials
    12ms
    SNHG10: A Novel Long Non-coding RNA with Multifaceted Roles in Human Cancers. (PubMed, Curr Pharm Des)
    This review focuses on the biological function and molecular mechanism of SNHG10 and its relationship with various malignant tumors. In addition, this review highlights the potential of SNHG10 to improve precision oncology and develop novel cancer therapies by investigating its upstream regulators, downstream targets, and interactions with nuclear and cytoplasmic processes.
    Journal
    |
    SNHG10 (Small Nucleolar RNA Host Gene 10)
    1year
    The emerging landscape of small nucleolar RNA host gene 10 in cancer mechanistic insights and clinical relevance. (PubMed, Cell Signal)
    The diverse biological functions and intricate mechanisms of SNHG10 highlight its considerable clinical relevance, positioning it as a potential pan-cancer biomarker and therapeutic target. This review aims to summarize the role of SNHG10 in tumorigenesis and cancer progression, clarify the molecular mechanisms at play, and explore its clinical significance in cancer diagnosis and prognosis prediction, along with its therapeutic potential.
    Review • Journal
    |
    SNHG10 (Small Nucleolar RNA Host Gene 10)
    over2years
    An angiogenesis-related lncRNA signature predicts the immune microenvironment and prognosis of breast cancer. (PubMed, Aging (Albany NY))
    Taken together, we constructed and verified a robust signature of eight ARLs for the prediction of survival in patients with breast cancer, and the characterization of the immune infiltration landscape. Our findings suggest that OTUD6B-AS1 could be a therapeutic target for patients with breast cancer.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • OTUD6B (OTU Deubiquitinase 6B) • CYTOR (Cytoskeleton Regulator RNA) • MED14OS (MED14 Opposite Strand) • MILIP (MYC Inducible LncRNA Inactivating P53) • OTUD6B-AS1 (OTUD6B Antisense RNA 1) • SNHG10 (Small Nucleolar RNA Host Gene 10)